Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and application
Autor: | Ying-Yi Zhang, D Michelle, Daniel G. Wright, Charles F. Arkin, M LeBlanc, Jeremy Wally, S Karandish, J McMannis, Martha Skinner, Geraldina Kica, Raymond L. Comenzo |
---|---|
Rok vydání: | 1998 |
Předmět: |
Adult
Male Transplantation Conditioning Lymphocyte Immunology Immunoglobulin Variable Region CD34 Antigens CD34 Cell Separation Biology Filgrastim Polymerase Chain Reaction Transplantation Autologous Cohort Studies Blood cell Andrology Granulocyte Colony-Stimulating Factor medicine Humans Immunology and Allergy Leukapheresis DNA Primers Hematopoietic Stem Cell Transplantation Amyloidosis Hematology Middle Aged Hematopoietic Stem Cells Clone Cells Hematopoiesis Granulocyte colony-stimulating factor medicine.anatomical_structure biology.protein Female Immunoglobulin Light Chains Stem cell Antibody medicine.drug |
Zdroj: | Transfusion. 38:60-69 |
ISSN: | 1537-2995 0041-1132 |
DOI: | 10.1046/j.1537-2995.1998.38198141500.x |
Popis: | BACKGROUND: Concern about tumor cell contamination in stem cell preparations has led to the use of CD34+ cell selection as a means of purging. Increasing the number of CD34+ cells per leukapheresis may help to provide an adequate dose of CD34+ cells. STUDY DESIGN AND METHODS: The reverse transcriptase polymerase chain reaction (RT-PCR) was employed to clone overexpressed clonotypic immunoglobulin light- chain variable region genes (Ig VL) from bone marrows of patients with primary light-chain amyloidosis (AL). Patient-specific primers were designed to evaluate stem cell collections for contamination. CD34+ cell selection was performed on components from AL patients who underwent mobilization with granulocyte-colony-stimulating factor (G- CSF) (filgrastim; 16 microg/kg/d for 4 days) and collection by large- volume leukapheresis (LVL;25L) on Days 4 and 5. The selected cells alone were transfused after patients received mephalan (200 mg/m2). RESULTS: Contamination was found in collections from 4 to 7 patients, which provided the rationale for a subsequent trial of CD34+ cell selection. The median number of CD34+ cells per kg collected on Days 4 and 5, and in toto, was 4.0 × 10(6)(1.1-12.7), 7.9 × 10(6)(1.8-12.7), and 10.7 × 10(6)(2.9-25.4), respectively (n = 9 patients). The median yield per selection was 38 percent, with a purity of 85 percent (45- 97%), and the viability of CD34+ cells averaged 96.4 +/− 3.6 percent (n = 18 selections). The median number of CD34+ cells infused was 5.9 × 10(6) per kg (2.1-10.1). In comparison with AL patients given unselected autografts, patients receiving selected CD34+ cells experienced similar reconstitution of neutrophils and platelets but slower lymphocyte recovery. CONCLUSION: Patients with AL often have contamination with clonotypic cells in their blood autografts. G-CSF mobilization and LVL provide components that allow the selection of adequate doses of CD34+ cells. The use of CD34+ cells in patients with AL achieves rapid neutrophil and platelet recovery but delayed lymphocyte recovery. CD34+ cell selection is feasible in the treatment of AL, but its effectiveness in purging clonotypic cells remains to be ascertained. |
Databáze: | OpenAIRE |
Externí odkaz: |